Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730522 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
A Phase 2 study, sponsored by Catalyst Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00730522 is a Phase 2 study that was terminated before completion, run by Catalyst Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT00730522, a Phase 2 study, was terminated before completion, sponsored by Catalyst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
Interventions
- DRUG Matching Placebo
- DRUG CPP-109 vigabatrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730522
The ClinicalTrials.gov registry entry for NCT00730522 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT00730522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730522 about?
NCT00730522 is a clinical study titled "Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence". The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
What is the current status of trial NCT00730522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2008-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00730522?
The interventions under investigation include: Matching Placebo (DRUG), CPP-109 vigabatrin (DRUG).
Who is sponsoring clinical trial NCT00730522?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.